thalidomide在试验室中增加了单细胞衍生的树突细胞的成熟和T助手1诱导能力
Mohsen Abbaszadeh1, Bahar Naseri2, Javad Masoumi2
1Molecular Medicine Department, Faculty of Modern Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
BioImpacts : BI
|April 21, 2025
概括
thalidomide治疗增强了树突细胞 (DC) 成熟和T辅助1 (Th1) 细胞的诱导. 这表明,用thalidomide治疗的DC可能在癌症免疫治疗中有效.
科学领域:
- 免疫学 免疫学 免疫学
- 细胞生物学 细胞生物学
背景情况:
- 树突细胞 (DCs) 通过呈现抗原和刺激T细胞,对适应性免疫至关重要.
- thalidomide及其衍生物以其免疫调节作用而闻名,对DCs有复杂的影响.
- 了解thalidomide对DC的影响对于其治疗应用至关重要.
研究的目的:
- 调查thalidomide对单细胞衍生的DCs的成熟和刺激能力的影响.
- 分析thalidomide治疗的DC如何影响自身T细胞的免疫反应.
主要方法:
- 单细胞衍生的DCs被差异化并用thalidomide或LPS治疗.
- 用流细胞计进行了DCs的表型分析.
- 对DC和共同培养的T细胞的基因表达通过实时PCR进行了评估.
主要成果:
- thalidomide治疗显著增加了DC表面标记物 (CD11c,HLA-DR,CD86) 和基因表达 (TNF-α,IL-12).
- 与thalidomide治疗的DCs共同培养增强了T细胞中的T-bet和IFN-γ表达.
- 用thalidomide治疗的DCs降低了T细胞中的FOXP3和TGF-β表达.
结论:
- 实验室thalidomide治疗促进了DCs中的免疫原体表型.
- 塔利多米德增强了DCs的T助手1 (Th1) 诱导能力.
- 这些发现表明thalidomide治疗的DC在癌症免疫治疗中的潜在应用.
更多相关视频
06:09Generation of Immature, Mature and Tolerogenic Dendritic Cells with Differing Metabolic Phenotypes
Published on: June 22, 2016
22.9K
11:34A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
Published on: April 11, 2025
140
相关概念视频
01:24T Cell Types and Functions
617
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
617
01:07Teratogenicity
2.3K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.3K